Rosenstein, Igal http://orcid.org/0000-0002-5078-9690
Nordin, Anna
Sabir, Hemin
Malmeström, Clas
Blennow, Kaj
Axelsson, Markus
Novakova, Lenka
Funding for this research was provided by:
Swedish State Support for Clinical Research (ALFGBG-71320, ALFGBG-722081, ALFGBG-984087)
NEURO Sweden
NEURO Gothenburg
Edith Jacobson’s Foundation
Amlövs foundation
Göteborg Foundation for Neurological Research
Helena Ahlin’s Foundation
University of Gothenburg
Article History
Received: 29 February 2024
Revised: 15 April 2024
Accepted: 16 April 2024
First Online: 26 April 2024
Declarations
:
: IR has received compensation for lectures from Biogen, Novartis, and Sanofi, and has served on advisory boards for Sanofi. AN has nothing to declare. HS has nothing to declare. CM has served at scientific advisory boards and/or held lectures for Biogen, Merck, Novartis, Roche, Sanofi. Serves as board member for Alzinova AB, Sweden KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. MA has received compensation for lectures and/or advisory boards from Biogen, Genzyme, and Novartis. LN has received lecture honoraria from Biogen, Novartis, Teva, Sanofi and has served on advisory boards for Merck, Janssen and Sanofi.